Endocrine Abstracts

Hypercortisolism has been reported to affect cardiac structure and performance. Subclinical Cushing’s syndrome (SCS) is increasingly being reported in incidentally discovered adrenal tumors; its hallmark is a mild autonomous cortisol hypersecretion without specific clinical syndrome of glucocorticoid excess. The aim of this study was to compare cardiac structure and function in patients with adrenal incidentaloma. Thirty patients (10 men, 15 women, 32–74 years) and 3...

Cabergoline (CAB), a potent dopamine agonist, is one of the most effective neuromodulatory drug in the second line treatment of patients with Cushing’s disease (CD). The aim of the current study was to estimate the predictive value of the acute CAB administration on short and long term responsiveness to CAB treatment. Twenty CD patients (6 males, 14 females, 12–60 years) entered the study. The acute CAB test was performed evaluating serum cortisol every hour for 6 h ...

Cushing’s syndrome (CS) is a severe disease caused by an endogenous glucocorticoid excess and it is correlated to an increased morbidity and mortality especially for sepsis and cardiovascular diseases, while hypertension, glucose intolerance or diabetes mellitus, and dyslipidemia are the most common systemic complications. The aim of this retrospective study was to evaluate the mortality and morbidity of patients with CS admitted at the Department of Endocrinology and Onc...

Cabergoline (CAB) was demonstrated to be effective in normalizing cortisol secretion in a subset of patients with Cushing’s disease (CD). The aim of the study was to evaluate the impact of chronic treatment with CAB on clinical, metabolic and hormonal parameters in CD patients. Twenty-six patients with CD (11 males, 15 females, 12–72 years) entered the study. Patients were divided into two groups, responders and non responders, according to the achievement or not of ...